Wealth Enhancement Advisory Services LLC Acquires 37,949 Shares of Gilead Sciences, Inc. $GILD

Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 633,185 shares of the biopharmaceutical company’s stock after purchasing an additional 37,949 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Gilead Sciences were worth $77,219,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences in the third quarter valued at approximately $26,000. Howard Hughes Medical Institute bought a new position in Gilead Sciences during the second quarter worth $30,000. MTM Investment Management LLC raised its stake in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the last quarter. Kilter Group LLC bought a new stake in Gilead Sciences in the 2nd quarter valued at $33,000. Finally, Millstone Evans Group LLC grew its position in Gilead Sciences by 58.7% in the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 118 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $137.21 on Monday. The firm has a market cap of $170.34 billion, a P/E ratio of 20.27, a price-to-earnings-growth ratio of 1.80 and a beta of 0.36. The firm’s 50-day simple moving average is $142.69 and its 200-day simple moving average is $127.98. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.4%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is presently 48.45%.

Analyst Ratings Changes

Several research analysts have recently issued reports on GILD shares. Mizuho boosted their price objective on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Jefferies Financial Group initiated coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 target price on the stock. Scotiabank upped their price target on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a report on Wednesday, February 11th. Deutsche Bank Aktiengesellschaft raised their price objective on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Finally, UBS Group boosted their price objective on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $157.62.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the sale, the chief executive officer directly owned 642,308 shares in the company, valued at $92,999,775.32. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the transaction, the director owned 8,920 shares of the company’s stock, valued at $1,101,620. This represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 309,280 shares of company stock worth $44,068,850 in the last quarter. Corporate insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.